503 related articles for article (PubMed ID: 14500756)
1. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells.
Masiello LM; Fotos JS; Galileo DS; Karin NJ
Bone; 2006 Jul; 39(1):72-82. PubMed ID: 16487757
[TBL] [Abstract][Full Text] [Related]
3. Agonist-induced endocytosis of lysophosphatidic acid-coupled LPA1/EDG-2 receptors via a dynamin2- and Rab5-dependent pathway.
Murph MM; Scaccia LA; Volpicelli LA; Radhakrishna H
J Cell Sci; 2003 May; 116(Pt 10):1969-80. PubMed ID: 12668728
[TBL] [Abstract][Full Text] [Related]
4. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
[TBL] [Abstract][Full Text] [Related]
5. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family.
Noguchi K; Ishii S; Shimizu T
J Biol Chem; 2003 Jul; 278(28):25600-6. PubMed ID: 12724320
[TBL] [Abstract][Full Text] [Related]
6. Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells.
Moughal NA; Waters CM; Valentine WJ; Connell M; Richardson JC; Tigyi G; Pyne S; Pyne NJ
J Neurochem; 2006 Sep; 98(6):1920-9. PubMed ID: 16945108
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate.
Im DS; Heise CE; Harding MA; George SR; O'Dowd BF; Theodorescu D; Lynch KR
Mol Pharmacol; 2000 Apr; 57(4):753-9. PubMed ID: 10727522
[TBL] [Abstract][Full Text] [Related]
9. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
Heasley BH; Jarosz R; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2004 Jun; 14(11):2735-40. PubMed ID: 15125924
[TBL] [Abstract][Full Text] [Related]
10. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors.
Fischer DJ; Nusser N; Virag T; Yokoyama K; Wang Da ; Baker DL; Bautista D; Parrill AL; Tigyi G
Mol Pharmacol; 2001 Oct; 60(4):776-84. PubMed ID: 11562440
[TBL] [Abstract][Full Text] [Related]
11. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands.
Kostenis E
J Cell Biochem; 2004 Aug; 92(5):923-36. PubMed ID: 15258916
[TBL] [Abstract][Full Text] [Related]
12. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury.
Okusa MD; Ye H; Huang L; Sigismund L; Macdonald T; Lynch KR
Am J Physiol Renal Physiol; 2003 Sep; 285(3):F565-74. PubMed ID: 12770838
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid stimulates prostaglandin E2 production in cultured stromal endometrial cells through LPA1 receptor.
Woclawek-Potocka I; Kondraciuk K; Skarzynski DJ
Exp Biol Med (Maywood); 2009 Aug; 234(8):986-93. PubMed ID: 19491366
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation.
Subramanian P; Karshovska E; Reinhard P; Megens RT; Zhou Z; Akhtar S; Schumann U; Li X; van Zandvoort M; Ludin C; Weber C; Schober A
Circ Res; 2010 Jul; 107(1):96-105. PubMed ID: 20360252
[TBL] [Abstract][Full Text] [Related]
15. Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.
Guillot E; Le Bail JC; Paul P; Fourgous V; Briand P; Partiseti M; Cornet B; Janiak P; Philippo C
J Pharmacol Exp Ther; 2020 Aug; 374(2):283-294. PubMed ID: 32409422
[TBL] [Abstract][Full Text] [Related]
16. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.
Xu Y; Jiang G; Tsukahara R; Fujiwara Y; Tigyi G; Prestwich GD
J Med Chem; 2006 Aug; 49(17):5309-15. PubMed ID: 16913720
[TBL] [Abstract][Full Text] [Related]
17. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells.
Shida D; Kitayama J; Yamaguchi H; Hama K; Aoki J; Arai H; Yamashita H; Mori K; Sako A; Konishi T; Watanabe T; Sakai T; Suzuki R; Ohta H; Takuwa Y; Nagawa H
Exp Cell Res; 2004 Dec; 301(2):168-78. PubMed ID: 15530853
[TBL] [Abstract][Full Text] [Related]
18. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.
Tokumura A; Sinomiya J; Kishimoto S; Tanaka T; Kogure K; Sugiura T; Satouchi K; Waku K; Fukuzawa K
Biochem J; 2002 Aug; 365(Pt 3):617-28. PubMed ID: 11982483
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
Durgam GG; Tsukahara R; Makarova N; Walker MD; Fujiwara Y; Pigg KR; Baker DL; Sardar VM; Parrill AL; Tigyi G; Miller DD
Bioorg Med Chem Lett; 2006 Feb; 16(3):633-40. PubMed ID: 16263282
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidylserine stimulates chemotactic migration in U87 human glioma cells.
Lee SY; Lee HY; Kim SD; Jo SH; Shim JW; Lee HJ; Yun J; Bae YS
Biochem Biophys Res Commun; 2008 Sep; 374(1):147-51. PubMed ID: 18616930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
